Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates

Company Performance - Compugen reported a quarterly loss of $0.07 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.11 per share a year ago, indicating a significant decline [1] - The company posted revenues of $1.47 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 91.58%, and a sharp decrease from year-ago revenues of $33.46 million [2] - Over the last four quarters, Compugen has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Movement and Outlook - Compugen shares have increased by approximately 18.3% since the beginning of the year, contrasting with a -0.5% decline in the S&P 500 [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the coming quarter at -$0.05 on $5 million in revenues, and -$0.12 on $33.58 million in revenues for the current fiscal year [7] - The Zacks Rank for Compugen is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - Compugen operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the top 29% of over 250 Zacks industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]